<ѻý>Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancerѻý> Defining high risk, considering role of Ki-67, BRCA mutations Mar 05, 2022
<ѻý>Older Patients With Low-Risk DCIS May Not Benefit From Surgery, Radiationѻý> Low rate of invasive recurrence, benefits of surgery and RT limited to patients under 70 Jan 05, 2022
<ѻý>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancerѻý> No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
<ѻý>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancerѻý> Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
<ѻý>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancerѻý> Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
<ѻý>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancerѻý> Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
<ѻý>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancerѻý> Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
<ѻý>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancerѻý> Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
<ѻý>Highly Mutated Breast Cancer Responds to Immunotherapyѻý> Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
<ѻý>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Siteѻý> Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
<ѻý>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Statusѻý> However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
<ѻý>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancerѻý> Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
<ѻý>Black Women Most at Risk for Post-Surgical Lymphedemaѻý> Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
<ѻý>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancerѻý> Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
<ѻý>Genomic Profiling Improves Outcomes in Breast Cancerѻý> PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
<ѻý>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancerѻý> Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
<ѻý>Artificial Intelligence Tool Gets High Marks in Reading Mammogramsѻý> Breast cancer screening results show AI's mettle in real-world dataset Dec 02, 2021
<ѻý>Year in Review: HER2-Positive Breast Cancerѻý> ADCs impress in second-line therapy, primary surgery debate, neoadjuvant PD-L1 falls short Nov 15, 2021
<ѻý>Low-Quality Mammography Leading to More Deaths in Black Women, Says Expertѻý> In cities like Chicago, Black women face higher breast cancer mortality versus white women Oct 26, 2021
<ѻý>No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancerѻý> Women with medially or centrally located tumors may be candidates, however, says researcher Oct 26, 2021
<ѻý>More Evidence for Safety of Accelerated Radiation in Early Breast Cancerѻý> Studies show low toxicity with few recurrences Oct 25, 2021
<ѻý>Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast Cancerѻý> Reduced risk of recurrence, distant relapse with adjuvant abemaciclib Oct 20, 2021
<ѻý>'Modest' Link Between Infertility and Postmenopausal Breast Cancerѻý> Study finds increased risk for younger women, those with primary infertility Oct 19, 2021
<ѻý>First CDK4/6 Inhibitor OK'd for Early, High-Risk Breast Cancerѻý> Abemaciclib approved with endocrine therapy for hormone receptor-positive/HER2-negative disease Oct 13, 2021
<ѻý>Almost Half of Breast Cancer Patients Use Cannabis, Survey Findsѻý> Common reasons for use include pain, anxiety, nausea, and insomnia Oct 12, 2021
<ѻý>Standard of Care Hard to Beat in HER2-Negative Breast Cancerѻý> Swapping letrozole for fulvestrant, in combination with palbociclib, did not improve PFS Oct 07, 2021
<ѻý>Women With Very Dense Breasts Benefit From MRI Screeningѻý> Dutch researchers recommend screening with MRI every 4 years Oct 01, 2021
<ѻý>Different Taxanes, Similar Outcomes in Advanced HER2-Positive Breast Cancerѻý> Results from docetaxel-based study appear applicable to paclitaxel, nab-paclitaxel Sep 29, 2021
<ѻý>What's Behind the Racial Differences in Women's Cancer Screening?ѻý> Existing medical conditions and social factors are likely driving gaps, researchers found Sep 24, 2021
<ѻý>In RA, Little Risk for Recurrent Cancer With Biologic Treatmentѻý> Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<ѻý>Chemo Plus Keytruda Boosts Overall Survival in Advanced TNBCѻý> KEYNOTE-355 regimen offers "transformative treatment" in PD-L1-positive disease, expert says Sep 20, 2021
<ѻý>ADC Makes a Case for Role in Metastatic HER2-Positive Breast Cancerѻý> Improved progression-free survival in previously treated disease with trastuzumab duocarmazine Sep 20, 2021
<ѻý>Combo Treatment Extends Survival in HR+HER2- Advanced Breast Cancerѻý> MONALEESA-2's "big message": 12.5-month boost in median OS with ribociclib-aromatase inhibitor Sep 19, 2021
<ѻý>Trastuzumab Deruxtecan: New Standard of Care in Pretreated, Advanced Breast Cancer?ѻý> DESTINY-Breast03 turns in "absolutely startling" PFS in HER2-positive metastatic disease Sep 18, 2021
<ѻý>Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancerѻý> 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Sep 17, 2021
<ѻý>Improved Survival With Surgery in Metastatic Breast Cancerѻý> Significant benefits in ER+, PR+, HER2+ disease, neoadjuvant vs adjuvant chemotherapy Aug 31, 2021
<ѻý>Benefits of Adjuvant Radiation in DCIS Persist Out to 15 Yearsѻý> Risk of ipsilateral breast recurrence more than halved in women with good-risk lesions Aug 27, 2021
<ѻý>Dense Breasts Linked to Increased Risk of Invasive Cancer in Older Womenѻý> Breast density, life expectancy could be factored into considerations for continued screening Aug 27, 2021
<ѻý>Genentech Pulls Atezolizumab's Breast Cancer Approvalѻý> Lack of FDA support amid "changes in the treatment landscape" cited in decision Aug 27, 2021
<ѻý>Breast Cancer Control Similar With Intermittent, Continuous Endocrine Therapyѻý> Better quality of life with treatment break during extended adjuvant therapy Aug 11, 2021